Edition:
India

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

3.12USD
19 Jan 2018
Change (% chg)

$0.08 (+2.63%)
Prev Close
$3.04
Open
$3.05
Day's High
$3.12
Day's Low
$3.05
Volume
99,556
Avg. Vol
187,588
52-wk High
$5.71
52-wk Low
$1.12

Select another date:

Fri, Jan 5 2018

BRIEF-Verastem Announces Increased Hercules Debt Facility

* VERASTEM INC - ANNOUNCED ENTRY INTO AN AMENDMENT TO ITS LOAN AND SECURITY AGREEMENT WITH HERCULES CAPITAL INC

BRIEF-Verastem Announces Pricing Of Public Offering Of Common Stock

* VERASTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Verastem Announces Public Offering Of Common Stock

* VERASTEM INC - INTENDS TO OFFER AND SELL $25 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

BRIEF-‍Verastem Announces Clinical Data From Pivotal Phase 3 Duo Study​

* ‍VERASTEM ANNOUNCES CLINICAL DATA FROM PIVOTAL PHASE 3 DUO™ STUDY​

BRIEF-Verastem reports Q3 loss per share of $0.61

* Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S

BRIEF-Verastem says ‍plans to submit NDA for duvelisib during Q1 of 2018​

* Verastem announces regulatory strategy for duvelisib, new drug application following guidance from FDA

BRIEF-Verastem makes milestone payment to Infinity Pharmaceuticals

* Verastem pays milestone payment to Infinity Pharmaceuticals

Verastem's blood cancer drug succeeds in late-stage trial

Verastem Inc said on Wednesday its drug to treat some types of blood cancer met the main goal of a late-stage study, sending the U.S. drug developer's shares up as much as 44.5 percent.

UPDATE 2-Verastem's blood cancer drug succeeds in late-stage trial

* Drug could rake in >$400 mln within 5 yrs of launch -analyst

BRIEF-Verastem expands duvelisib development program to include peripheral T-cell lymphoma

* Verastem expands duvelisib development program to include peripheral T-cell lymphoma

Select another date: